Hélène Tran, Ph.D.
Research Director, Head of Antisense Oligonucleotide Therapeutics, Neurology Therapeutic Area, Servier Research Institute, France

Biography:

Hélène Tran is a Director in the Neuroscience Therapeutic Area at the Servier Research & Development Institute in Paris-Saclay, where she leads the antisense oligonucleotide (ASO) therapeutics platform. Her team is dedicated to advancing ASO therapies for brain disorders and addressing key technological challenges related to central nervous system delivery, safety, and stability.

Before joining Servier in late 2018, Hélène was an Instructor at UMASS Medical School in the laboratory of Professor Robert Brown. Her research there centered on (1) elucidating the role of an abnormal repeat RNA expansion in the C9ORF72 gene, the most common genetic cause of Amyotrophic Lateral Sclerosis (ALS) and (2) developing ASO therapies in collaboration with Dr. Jonathan Watts’ team at the RNA Therapeutics Institute and the team at Wave Life Sciences.

Hélène began her scientific career at the University of Lille in France, where she investigated the contribution of repeat RNA to neuronal toxicity in myotonic dystrophy where she received her Ph.D. late 2010.